[New MAA: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma].

Bull Cancer

Assistance publique-Hôpitaux de Paris (AP-HP), université de Paris, institut universitaire du Cancer Paris-Nord, hôpital Bichat-Claude Bernard, service d'oncologie thoracique-CIC, Inserm 1425, 46, rue Henri-Huchard, 75018 Paris, France; Institut Curie, centre de recherche, U830 Inserm cancer hétérogénéité et plasticité, 75231 Paris cedex 05, France.

Published: January 2022

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bulcan.2021.07.010DOI Listing

Publication Analysis

Top Keywords

[new maa
4
maa first-line
4
first-line nivolumab
4
nivolumab ipilimumab
4
ipilimumab unresectable
4
unresectable malignant
4
malignant pleural
4
pleural mesothelioma]
4
[new
1
first-line
1

Similar Publications

Need for and update on clinical trials for uncomplicated type B aortic dissection.

JVS Vasc Insights

January 2024

Academic Department of Vascular Surgery, South Bank Section, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, British Heart Foundation Centre of Research Excellence, St Thomas' Hospital, London, UK.

The mainstay of management for uncomplicated type B aortic dissection is currently optimal medical therapy, targeting blood pressure and heart rate, along with serial imaging. There is a paucity of data that informs whether early intervention with thoracic endografting in this group of patients will promote aortic remodeling and better long-term outcomes. Investigations to date, including the Investigation of Stent Grafts in Aortic Dissection (INSTEAD), INSTEAD-XL, and Acute Dissection: Stent Graft or Best Medical Therapy (ADSORB) studies, have compared thoracic endovascular aortic repair (TEVAR) with optimal medical therapy in patients with uncomplicated type B aortic dissection but have not shown a benefit for TEVAR conclusively.

View Article and Find Full Text PDF

Uniform, mesoporous copper(II) oxide nanospindles (CuO NSs) were synthesized via a method based on templated hydrothermal oxidation of copper in the presence of monodisperse poly(glycerol dimethacrylate--methacrylic acid) nanoparticles (poly(GDMA--MAA) NPs). Subsequent decoration of CuO NSs with a CaO nanoshell (CuO@CaO NSs) yielded a nanozyme capable of Cu(I)/Cu(II) redox cycling. Activation of the Cu(I)/Cu(II) cycle by exogenously generated HO from the CaO nanoshell significantly enhanced glutathione (GSH) depletion.

View Article and Find Full Text PDF

Background and objectives A modified aligner appliance with nickel-titanium springs (MAA) is a relatively new appliance that has not received extensive attention in orthodontics. This study evaluated the patient-reported outcomes when orthodontic treatment was provided using a modified aligner appliance to treat mild lower incisor crowding. Materials and methods This prospective cohort study consisted of 42 patients (11 males and 31 females; mean age 21.

View Article and Find Full Text PDF

Evaluating post-cardiac arrest blood pressure thresholds associated with neurologic outcome in children: Insights from the pediRES-Q database.

Resuscitation

December 2024

Department of Pediatrics, Division of Critical Care Medicine, Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, 1184 5th Ave, New York, NY 10029, USA.

Background: Current Pediatric Advanced Life Support Guidelines recommend maintaining blood pressure (BP) above the 5th percentile for age following return of spontaneous circulation (ROSC) after cardiac arrest (CA). Emerging evidence suggests that targeting higher thresholds, such as the 10th or 25th percentiles, may improve neurologic outcomes. We aimed to evaluate the association between post-ROSC BP thresholds and neurologic outcome, hypothesizing that maintaining mean arterial pressure (MAP) and systolic blood pressure (SBP) above these thresholds would be associated with improved outcomes at hospital discharge.

View Article and Find Full Text PDF

Cerebral Hemodynamic Responses to Disease-Modifying and Curative Sickle Cell Disease Therapies.

Neurology

January 2025

From the Department of Neurology (M.A.A., W.R., A.K.S., M.J.D.), Department of Radiology and Radiological Sciences (D.M., L.T.D., L.C.J.), Division of Pediatric Neurology, Department of Pediatrics (S.M.D., L.L.M., L.C.J.), Division of Hematology and Oncology, Department of Medicine (A.A.K., M.R.D.), and Department of Psychiatry and Behavioral Sciences (M.J.D.), Vanderbilt University Medical Center, Nashville; Vanderbilt-Meharry Center of Excellence in Sickle Cell Disease (A.A.K., M.R.D.), Nashville; and Department of Electrical and Computer Engineering (M.J.D.), Vanderbilt University, Nashville, TN.

Background And Objectives: Sickle cell disease (SCD) is a hemoglobinopathy resulting in hemoglobin-S production, hemolytic anemia, and elevated stroke risk. Treatments include oral hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation (HSCT). Our objective was to evaluate the neurologic relevance of these therapies by characterizing how treatment-induced changes in hemoglobin (Hb) affect brain health biomarkers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!